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Abstract
Background: Recent evidence indicates that long noncoding RNAs (lncRNAs) play pivotal roles in the regulation of
cellular processes and are found to be dysregulated in a variety of cancers. LINC00261 is an lncRNA that is aberrantly
expressed in gastric cancer (GC). The clinical role of LINC00261 in GC and molecular mechanisms remains to be found.
Methods: Real-time polymerase chain reaction (PCR) was used to examine LINC00261 expression in GC cell lines/
tissues compared with normal epithelial cells/adjacent non-tumorous tissues. Gain and loss of function approaches
were used to investigate the biological role of LINC00261 in GC cells. The effects of LINC00261 on cell viability were
evaluated by MTT and colony formation assays. Wound healing assay, cell migration and invasion assays, and nude
mice were used to examine the effects of LINC00261 on tumor cell metastasis in vitro and in vivo. Protein levels of
LINC00261 targets were determined by western blot and immunohistochemistry.
Results: LINC00261 was downregulated in GC cell lines and cancerous tissues, as compared with normal gastric epithelial
cells and adjacent noncancerous tissue samples. Low LINC00261 expression was correlated with deeper tumor invasion
(P < 0.001), higher tumor stage (P = 0.013), and lymphatic metastasis (P = 0.006). Univariate and multivariate
analyses indicated that low LINC00261 expression predicted poor prognosis. Ectopic expression of LINC00261
impaired cell migration and invasion, leading to the inhibition of metastasis in vitro and in vivo. Knockdown of
LINC00261 expression promoted cell migration and invasion in vitro. Overexpression of LINC00261 was found to
play a key role in epithelial–mesenchymal transition (EMT) through the regulation of E-cadherin, N-cadherin, and
Vimentin expression.
Conclusions: Low expression of the lncRNA LINC00261 occurs in GC and is associated with poor prognosis. LINC00261
suppresses GC metastasis by regulating EMT. Thus, LINC00261 plays an important role in the progression and metastasis
of GC.
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Background
Gastric cancer (GC) represents the fourth most common
malignancy in the world and second leading cause of
cancer-related deaths worldwide, with particularly high
frequencies in East Asia [1]. Although GC is curable if
detected early, most patients are diagnosed in the ad-
vanced stage and have poor prognosis [2]. Tumor invasion
and metastasis are the main causes accounting for the
poor prognosis [3]. The clinical stage, based on the TNM
classification system, at the time of diagnosis is currently
the most important prognostic factor, and the molecular
mechanism involved in the progression and metastasis of
GC remains unknown [4]. Thus, novel prognostic factors
that are associated with GC progression and metastasis
would be of great clinical relevance.
Apart from about 2 % protein-coding genes, more
than 90 % of the genome is transcribed as noncoding
RNAs (ncRNAs), indicating that ncRNAs could play sig-
nificant regulatory roles in complex organisms [5, 6].
One subcategory of these transcripts, called long non-
coding RNAs (lncRNAs), comprises ncRNAs that are
more than 200 nucleotides in length. Accumulating evi-
dence demonstrates that lncRNAs play roles in a variety
of biological processes, including chromatin remodel-
ing, cell differentiation, and immune responses [7–9].
In addition, recent reports have showed that some
lncRNAs exhibit distinct gene expression patterns and
play significant roles during cellular development in
various types of carcinomas [10–12]. However, the
overall pathophysiological contributions of lncRNAs to
gastric carcinoma remain largely obscure. Functional
lncRNAs can be used for cancer diagnosis and progno-
sis and serve as potential therapeutic targets; thus,
lncRNAs can be considered as a new diagnostic and
therapeutic gold mine in cancer [13]. The lncRNA pro-
filing study revealed that lncRNA LINC00261, an
lncRNA mapped to 20p11.21, was found to be down-
regulated in GC tissues compared to normal tissue
samples [14]. However, the role of LINC00261 in GC
progression remains unknown.
In this study, we found that LINC00261 expression
was reduced in GC tissues and cell lines. Low expression
of LINC00261 was associated with clinicopathological
characteristics and poor prognosis in GC patients. Ec-
topic expression of LINC00261 in gastric cells signifi-
cantly inhibited cell migration and invasion. Conversely,
depletion of LINC00261 promoted these activities.
Moreover, we also showed that alteration of LINC00261
expression can influence E-cadherin, N-cadherin, Fibro-
nectin1 (FN1), and Vimentin protein levels, which indi-
cated that LINC00261 affected GC cell invasion and
metastasis partly via epithelial–mesenchymal transition
(EMT). These studies advance our understanding of the
role of lncRNAs, such as LINC00261 as a regulator of
pathogenesis of GC, and facilitate the development of
lncRNA-directed diagnostics and therapeutics.
Results
LINC00261 expression and clinicopathological factors in
GC
A human lncRNA microarray dataset (GSE13911) (38
paired cancer and noncancer tissues) was obtained to
analyze differentially expressed lncRNAs between GC
and paired non-tumor tissues. Twenty lncRNAs had an
obvious fold change in GC tissues when compared with
corresponding non-tumor tissues as supplied in Table 1.
LINC00261 expression levels were the most downregu-
lated in this database (Fig. 1a), which is consistent with a
previous report [14]. To ensure that conclusions derived
from these results are reliable, we have compared the
LINC00261 expression between paired GC and normal
tissues (n = 138) and tested for statistical significance by
Student’s paired t test. Analysis of tumor/non-tumor
adjacent tissue (T/N) ratios for LINC00261 expression
of 138 patients revealed that LINC00261 expression
was decreased in approximately 80 % GC patient tissues
(P < 0.001, Fig. 1b). Reverse transcription (RT)-qPCR as-
says were further developed to quantify LINC00261 in GC
cell lines, including MGC803, BGC823, MKN28, MKN45,
and SGC7901, and in the normal gastric epithelium cell
Table 1 Twenty candidate lncRNAs expressed with more than
twofold changes compared with corresponding non-tumor tissues
Fold change P value FDR value Gene name
5.3 <0.001 <0.001 UCA1
4.6 <0.001 <0.001 H19
4.8 <0.001 0.003269372 HOXA11-AS
4.0 <0.001 <0.001 LOC100131046
3.6 0.006 0.02 BCAR4
3.2 <0.001 <0.001 LINC00152
2.8 0.0055 0.019 ANKRD30BP2
2.6 <0.001 <0.001 KRT16P2
2.5 <0.001 <0.001 HMGB3P1
2.3 <0.001 <0.001 SNHG10
2.1 <0.001 <0.001 SNHG5
2.2 <0.001 <0.001 HOTAIR
2.2 <0.001 <0.001 SPRR2C
2.0 <0.001 <0.001 MAFG-AS1
0.50 <0.001 <0.001 RP11-834C11.4
0.42 <0.001 <0.001 RP11-363E7.4
0.35 <0.001 <0.001 RP11-734 K23.9
0.31 <0.001 <0.001 RP11-160 N1.10
0.23 <0.001 <0.001 LINC00982
0.18 <0.001 <0.001 LINC00261
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line GES1. Significantly lower expression of LINC00261
was found in MKN28 (P = 0.008), MKN45 (P = 0.038),
BGC823 (P = 0.003), SGC7901 (P = 0.022), and MGC803
(P = 0.045) than in GES-1 (Fig. 1c).
We plotted a receiver operating characteristic (ROC)
curve with the non-tumorous tissues adjacent to the
tumor tissues as a control based on the GSE13911 and
our collected tissues. The cutoff value for predicting GC
tissues from normal tissues was 5.22 (normalized inten-
sity value) and 9.02 (Δ Ct value). The area under the
ROC curve (AUC) was 0.921 (95 % confidence interval
(CI) = 0.836–0.970, P < 0.001) and 0.812 (95 % CI = 0.743–
0.869, P < 0.001) (Fig. 1d, e). The sensitivity and specificity
were 0.97 and 0.87 and 0.76 and 0.75, respectively. To
assess the correlation of LINC00261 expression with clini-
copathological data, the expression levels of LINC00261
in tumor tissues were categorized as low or high in rela-
tion to the median value of relative LINC00261 expression
(3.8-fold, noncancerous/tumors). Clinicopathological fac-
tors were analyzed in the high and low LINC00261 ex-
pression groups. As shown in Table 2, the low LINC00261
expression group (n = 69) showed greater invasion depth
(P < 0.001), higher tumor stage (P = 0.013), and more fre-
quent lymphatic metastasis (P = 0.006) than the high
LINC00261 expression group (n = 69). However, there was
no significant correlation between LINC00261 expression
and other clinicopathological features such as age, sex,
tumor location, tumor size, histological grade, and distant
metastasis (P > 0.05). The clinical data of all patients is
shown in Additional file 1: Table S2.
LINC00261 is a bona fide ncRNA in GC
We first identified the full poly (A)-positive sequence of
LINC00261 through rapid amplification of cDNA ends
(RACE) and performed polymerase chain reaction (PCR)
analysis to confirm the gene size of LINC00261. The
Fig. 1 Decreased expression of LINC00261 in gastric cancer tissues and cell lines. a LINC00261 expression is analyzed based on GSE13911 database.
b Real-time PCR analysis of LINC00261 expression in normal gastric epithelial cell line (GES-1) and gastric cancer cells. Experiments were performed in
triplicate. Bars: SD; *P < 0.05, **P < 0.01. c Examined LINC00261 expression by qRT-PCR in 138 paired human gastric cancer tissues and adjacent
noncancerous tissues (paired t test, P < 0.001). Data are represented as log2-fold changes (cancer/normal), with “<−1” indicating underexpression and
“>1” indicating overexpression. The patients were divided into a low LINC00261 expression group (69) and a high LINC00261 expression group (69),
according to the median value of relative LINC00261 expression (3.8-fold, noncancerous/tumors). d, e ROC curves were conducted for prediction of
gastric cancer tissues based on GSE13911 database and using qPCR-based LINC00261 expression level. The AUC was 0.921 (d) and 0.812 (e)
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RACE results identified two isoforms of LINC00261
(Additional file 2: Table S3). In addition, txCdsPredict,
created by UCSC, was used to calculate its protein-
coding potential, and a score was assigned based on its
coding potential; we considered the transcript as
ncRNA when the score was less than 800 [15]. The
txCdsPredict score for LINC00261 was 245, indicating
that LINC00261 has no protein-coding potential. We
verified that LINC00261 was indeed an ncRNA through
analysis of the sequences by ORF Finder from the National
Center for Biotechnology Information and Coding Poten-
tial Calculator (CPC) [16]. ORF Finder failed to predict a
protein of more than 205 amino acids (Fig. 2a), and the
CPC score is −1.21477 (Fig. 2b). Moreover, LINC00261
does not contain a valid Kozak sequence, which further
supports that LINC00261 has no protein-coding potential.
Low LINC00261 expression is associated with poor
prognosis in patients with GC
Kaplan–Meier analysis and log-rank test were used to
evaluate the effects of LINC00261 expression and clinico-
pathological characteristics on disease-free survival (DFS).
The results showed that patients in the low LINC00261
expression group had a higher recurrence rate (median
DFS 19 months) than those in the high LINC00261
expression group (median DFS 35 months; P = 0.004;
Fig. 3a). The 3-year DFS was 32.8 % in the low LINC00261
expression group, while 45.3 % in the high LINC00261
expression group. Moreover, the expression of LINC00261
was strongly correlated with DFS in the advanced clinical
stages (stages III and IV; Fig. 3d, e). However, in patients
in clinical stages I and II, no significant differences in DFS
was found between those with low and high LINC00261
expression (Fig. 3b, c). Univariate analyses of clinical vari-
ables considered as potential predictors of survival are
shown in Table 3. Further analysis in a multivariate Cox
proportional hazards model showed that LINC00261 ex-
pression, together with TNM stage, was strongly associated
with DFS. LINC00261 expression was an independent
prognostic indicator of DFS (hazard ratio (HR) = 0.551;
95 % (CI), 0.323–0.940; P = 0.029) in patients with GC
(Table 3).
LINC00261 exhibits an insignificant effect on GC cell
proliferation, but represses GC cell migration and
invasion in vitro
To gain further insight into the biologic pathways involved
in GC pathogenesis stratified by the median of LINC00261
expression level, Gene Set Enrichment Analysis (GSEA)
analysis was performed in GSE13911 datasets. Enrichment
plots of GSEA showed that the gene signatures of cell adhe-
sion were more correlated with patients with LINC00261
lower expression versus patients with LINC00261 higher
expression in the dataset (Fig. 4a). The top-scoring genes
Table 2 Correlation between LINC00261 expression and
clinicopathological characteristics of gastric cancer
Clinical parameter LINC00261 Chi-squared
test P value
High-expression
cases (n = 69)
Low-expression
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recurring in the pathway included key cancer genes, such
as E-cadherin, N-cadherin, CD44, matrix metalloproteinase
(MMP)-2, MMP-9, and FN1 (Additional file 3: Table S4).
Correlation analysis based on GSE13911 datasets showed
that LINC00261 expression was positively correlated with
E-cadherin and negatively related to N-cadherin and FN1
(Fig. 4b, c, d). Further real-time PCR data confirmed that
alteration of LINC00261 expression dramatically affected
the key gene signatures which are involved in tumor metas-
tasis (Fig. 4e, f), suggesting that LINC00261 may be a key
regulator in GC progression.
We further evaluated the biology function of LINC00261
in GC cells. LINC00261 was overexpressed by transfecting
the pcDNA3.1-LINC00261 vector into the MGC823 cell
line, which harbored the lowest expression level of
LINC00261. LINC00261-overexpressing cells were selected
by adding G418. In addition, LINC00261 was depleted in
MGC803 cells, which exhibit high LINC00261 expression.
To exclude off-target effects, we designed two different
small interfering RNAs (siRNAs); both were considered
appropriate for LINC00261 knockdown. The ectopic ex-
pression and knockdown of LINC00261 in the cells was
confirmed by qRT-PCR (Fig. 5a). However, none of the
MTT assays and cell cycle analysis detected a significant
proliferative effect of LINC00261 in either the MGC803 or
the BGC823 cell line (Fig. 5b, c). Subsequently, we ob-
served the effects on cell migration and invasion. As shown
in Fig. 6a, BGC823 cells, which have naturally low
LINC00261 expression, after transfecting of pcDNA3.1-
LINC00261 overexpression vector, exhibited a notably
lower scratch-closure rate (migration inhibition) than that
observed in controls infected with empty vector. Moreover,
after the knockdown of LINC00261, MGC803 cells, which
have naturally high LINC00261 expression, displayed a
higher scratch-closure rate (migration promotion) than
that in the control cells. Furthermore, cell motility was also
measured using migration and invasion assays. Compared
with the control cells, LINC00261-overexpressing BGC823
cells showed markedly repressed migration and invasion
ability; likewise, knockdown of LINC00261 signifi-
cantly stimulated migration and invasion by MGC803
cells (P < 0.05; Fig. 6b). These findings indicate that
LINC00261 may be closely associated with invasion
and migration in GC cell lines.
LINC00261 suppresses GC cell metastasis in vivo
To validate the effects of LINC00261 on the metastasis
of GC cells in vivo, BGC823 cells stably transfected
with pcDNA3.1-LINC00261 were injected into nude
mice. Metastatic nodules on the surface of the lungs
were counted after 7 weeks. Ectopic overexpression of
LINC00261 reduced the number of metastatic nodules
compared with those in the control group (Fig. 6c, d).
This difference was further confirmed following the
Fig. 2 LINC00261 is a long noncoding RNA. a Lack of open reading frame in the 4924-bp LINC00261 was verified by ORF Finder. b Coding Potential
Calculator (CPC) showed that the CPC score of LINC00261is −1.21477, indicating LINC00261 has no coding protein potential
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examination of the entire lungs and through hematoxylin
and eosin (HE) staining of lung sections (Fig. 6e). Our in
vivo data complemented the results of the functional in
vitro studies involving LINC00261.
LINC00261 influences GC cell EMT
We conducted western blot assays to detect the expres-
sion of EMT-induced markers (E-cadherin, N-cadherin,
FN1, and Vimentin) in cells overexpressing or decreas-
ing LINC00261. Our findings showed that increased
LINC00261 expression levels induced E-cadherin expres-
sion and decrease that of N-cadherin, Vimentin, and FN1,
while depletion of LINC00261 inhibited E-cadherin expres-
sion and promoted N-cadherin, Vimentin, and FN1 expres-
sion (Fig. 7a). Moreover, overexpression of LINC00261
markedly increased the levels of E-cadherin, while decreas-
ing N-cadherin and Vimentin expression in the xenograft
tumors (Figs. 7b). These data support our hypothesis that
LINC00261 influences the malignant phenotype by regulat-
ing EMT.
Discussion
Many lncRNAs have been implicated in various types of
cancers. Reportedly, the lncRNAs of the class MALAT-1
have been found to promote cell motility in lung adenocar-
cinoma cells [17]. PCGEM1 overexpression and PRNCR1
have been found to be involved in the development of
prostate cancer [18, 19]. Recent findings have also sug-
gested that many lncRNAs have important roles in GC.
MALAT1 and HOTAIR were recently reported to drive
Fig. 3 The prognostic significance of LINC00261 in gastric cancer patients. a Kaplan–Meier analysis of disease-free survival (DFS) based on LINC00261
expression in all 138 patients. b–e Kaplan–Meier analysis of DFS based on LINC00261 expression in gastric cancer patients in stages I (b), II (c), III (d),
and IV (e)
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GC development and promote peritoneal metastasis. Xu et
al. revealed that the lncRNA FENDRR inhibits invasive and
metastatic behavior in GC cells [10]. TINCR was reported
to promote GC proliferation by accelerating KLF2 mRNA
degradation [11]. Therefore, the identification of GC-
associated lncRNAs may provide a missing piece of the
well-known oncogenic and tumor suppressor network
puzzle.
Previous profiling study identified that LINC00261 was
downregulated in GC tissues compared to normal tissue
samples [14]. However, its function in carcinogenesis and
tumor progression is unclear. In this study, we confirmed
that LINC00261 levels were decreased in GC cells and tis-
sues compared with the normal gastric epithelial cells and
adjacent normal tissues. LINC00261 can serve as a bio-
marker to distinguish cancer tissue with non-tumor tissue
in GC. Moreover, low LINC00261 expression was signifi-
cantly correlated with aggressive tumor characteristics
(greater invasion depth, higher tumor stage, and lymphatic
metastasis) and poor prognosis. When the patients
were subdivided into four groups according to tumor
stage, we found that LINC00261 expression could dis-
tinguish patients with different outcomes in stages III
and IV. However, we did not observe a significant cor-
relation between LINC00261 expression and clinical
outcomes in the early clinical stages of GC, probably
due to better outcome in the early stage of GC after
treatment of operation. Univariate and multivariate
analyses indicated that DFS were significantly better
among patients with high LINC00261 expression than
in patients with low LINC00261 expression in the same
stage. Multivariate analysis demonstrated that LINC00261
expression was an independent prognostic factor for GC
patients. This suggests that LINC00261 might be a prom-
ising prognostic and diagnostic biomarker in GC patients.
As low LINC00261 expression was associated with an
aggressive tumor phenotype in GC, we speculated that
LINC00261 could play a significant role in tumor biology.
Initially, we chose representative cell lines of GC and in-
vestigated their LINC00261 expression in comparison to a
non-tumoral gastric cell line. We observed that all of the
five tumor cell lines exhibited low LINC00261 expression,
which corroborated our previous findings. We next deter-
mined whether LINC00261 expression influenced tumor-
like characteristics, such as proliferation and metastasis.
Ectopic expression of LINC00261 inhibited cell migra-
tion and invasion, whereas knockdown of endogenous
LINC00261 expression significantly enhanced these
capacities. Moreover, increased LINC00261 expression
significantly reduced the number of metastatic nodules
on the lungs in vivo. However, no significant effect on
cellular proliferation was observed after ectopic expres-
sion or knockdown of LINC00261. This is in line with
our clinical findings that LINC00261 was significantly
Table 3 Univariate and multivariate Cox regression analyses LINC00261 for DFS of patients in the study cohort (n = 138)
Variables DFS
HR 95 % CI P value
Univariate analysis
Age (<50 vs. >50 years) 0.874 0.537–1.424 0.589
Gender (male vs. female) 0.802 0.484–1.329 0.392
Location (distal vs. middle + proximal) 0.793 0.487–1.292 0.351
Tumor size (>5 vs. <5 cm) 1.336 1.041–1.714 0.023*
Histologic differentiation (well + moderately vs. poorly + undifferentiated) 1.626 0.966–2.738 0.068
Invasion depth (T1 + T2 vs. T3 + T4) 1.174 0.721–1.911 0.518
TNM stage (III + IV vs. I + II) 2.620 1.561–4.395 <0.001*
Lymphatic metastasis (no vs. yes) 0.749 0.583–0.963 0.024*
Regional lymph nodes (PN2 + PN3 vs. PN0 + PN1) 1.818 1.111–2.972 0.017*
Distant metastasis (no vs. yes) 0.654 0.482–0.888 0.007*
Expression of LINC00261 (high vs. low) 0.494 0.300–0.812 0.005*
Multivariate analysis
TNM stage (III + IV vs. I + II) 1.805 1.090–2.990 0.022*
Lymphatic metastasis (no vs. yes) 0.887 0.665–1.246 0.125
Regional lymph nodes (PN2 + PN3 vs. PN0 + PN1) 1.117 0.592–2.111 0.732
Tumor size (>5 vs. <5 cm) 1.086 0.835–1.433 0.510
Distant metastasis (no vs. yes) 0.584 0.294–1.162 0.126
Expression of LINC00261 (high vs. low) 0.551 0.323–0.940 0.029*
*P < 0.05
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Fig. 4 (See legend on next page.)
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(See figure on previous page.)
Fig. 4 GSEA in LINC00261 higher/lower expression gastric cancer patients and the correlation between of LINC00261 and its target genes. a GSEA
comparing LINC00261 lower expression group (red) against LINC00261 higher expression group (blue) of patients with gastric cancer in the GSE13911
dataset, illustrating distinct pathways and biologic processes between both subgroups. Enrichment plots are shown for a set of activated genes related
to cell adhesion in GSE13911 patients’ dataset. The enrichment score (ES, green line) means the degree to which the gene set is overrepresented at the
top or bottom of the ranked list of genes. Black bars indicate the position of genes belonging to the gene set in the ranked list of genes included in
the analysis. A positive value indicates more correlation with “LINC00261 lower expression” patients and a negative value indicates more correlation
with “LINC00261 higher expression” patients. b–d The Pearson correlation analysis of LINC00261 expression with target gene based on GSE13911
patients’ database. LINC00261 is negative related to FN1 (b) and N-cadherin (d), while positive correlated with E-cadherin (c). e, f qPCR analysis of
LINC00261 expression levels following the treatment of BGC823 cells with empty vector and pcDNA3.1-LINC00261 (e), and the treatment of MGC803
cells with scrambled siRNA and si-LINC00261 (f). Experiments were performed in triplicate. Bars: SD; *P < 0.05, **P < 0.01
Fig. 5 Effect of LINC00261 on gastric cancer cell proliferation and cell cycle. a The expression of LINC00261 in stable BGC823 cell clones infected
with pcDNA3.1-LINC00261 and in MGC803 cells transfected with siRNA against LINC00261was detected by qPCR. b MTT assays were performed
to determine the proliferation of BGC823 and MGC803 cells. c Cell cycle analysis determined the relative cell numbers in each cell cycle phase
after propidium iodide staining of LINC00261-upregulated BGC823 cells and LINC00261-depletion MGC803 cells. Numbers inside bars represent
percentages of cells in each phase
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Fig. 6 (See legend on next page.)
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correlated with invasion depth, tumor stage, and
lymphatic metastasis, but not tumor size. These results
revealed that LINC00261 might impact the prognosis
of GC by affecting cell migration and invasion.
To explore the molecular mechanism through which
LINC00261 contributes to invasion and metastasis in
GC, we investigated potential target proteins involved in
cell motility and matrix invasion. The EMT plays crucial
roles during cancer initiation and progression, especially
in cancer metastasis [20–22]. Previous data has been re-
vealed that lncRNAs regulate tumor cell metastasis by
affecting the EMT process [23, 24]. Hallmarks of EMT
are the loss of E-cadherin expression and the aberrant
expression of N-cadherin and Vimentin. Therefore, we
determined the levels of these EMT-induced markers
following overexpression or inhibition of LINC00261.
(See figure on previous page.)
Fig. 6 Effects of LINC00261 on gastric cancer cell migration and invasion in vitro and in vivo. BGC823 cells were transfected with pcDNA3.1-LINC00261,
and MGC803 cells were transfected with si-LINC00261. a Wound healing assays were used to investigate the migratory ability of gastric cancer cells.
Experiments were performed in triplicate. Bars: SD; **P < 0.01. b Transwell assays were used to investigate changes in the migratory and invasive abilities
of gastric cancer cells. Experiments were performed in triplicate. Bars: SD; *P < 0.05 and **P < 0.01. c, d Stable BGC823 cells transfected with pcDNA3.1-
LINC00261 and an empty vector were separately injected into the tail veins of athymic mice. The lungs were harvested from the mice in
each experimental group, and tumor nodules visible on lung surfaces were counted. The assay was independently conducted twice. Bars:
SD; *P < 0.05 and **P < 0.01. e Visualization of the entire lung and hematoxylin and eosin (HE)-stained lung sections
Fig. 7 LINC00261 overexpression suppresses GC cell invasion and metastasis by affecting the EMT. a Western blot analysis of E-cadherin, N-cadherin, FN1,
and Vimentin expression in GC cells treated with pcDNA3.1-LINC00261 and siRNAs-LINC00261. b Representative E-cadherin, N-cadherin and Vimentin
protein levels in xenograft tumors evaluated by immunohistochemistry. c Correlation analysis performed between E-cadherin, N-cadherin, and Vimentin
expression levels and the different xenograft tumor groups
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Our results indicated that LINC00261 mediated inhibi-
tory effects on GC cell metastasis suppression, possibly
by affecting the EMT. As a central differentiation
process, EMT allows for the remodeling of tissues dur-
ing the early stages of embryogenesis and is implicated
in the promotion of tumor cell invasion and metastasis.
Therefore, as regulators of EMT, lncRNAs could be
suitable candidates for intervention in the treatment of
cancer. In recent years, molecularly targeted therapeu-
tics for key molecular drivers of cancer progression has
been developed [25]. LINC00261, as an important regu-
lator of EMT, promise to serve as a drug target. Drugs
which could regulate the expression of LINC00261 have
clinical application prospects, so clinical test or assay
could be developed to test these.
Conclusions
In summary, our study showed that LINC00261 is dra-
matically downregulated in GC tissues and cell lines and
that the low expression of LINC00261 is significantly as-
sociated with invasion depth, tumor stage, lymphatic
metastasis, and patients’ survival time. Moreover, upreg-
ulation of LINC00261 has the effect of suppressing GC
cell migration and invasion in vitro and in vivo by tar-
geting EMT markers. Further insights into the functional
and clinical implications of LINC00261 and its targets
may help with the treatment of GC.
Methods
Computational analysis
Human microarray datasets were downloaded from NCBI’s
Gene Expression Omnibus (GEO, http://www.ncbi.nlm.
nih.gov/geo/) and are accessible through GEO series ac-
cession number GSE13911. GEO database and back-
ground were adjusted using Robust Multichip Average.
GATExplorer was used to process microarrays on a
local computer for gene expressions of lncRNAs [26].
This GATExplorer provides a series of R packages, de-
signed to be used with BioConductor tools, which allow
applying in a simple way the probe mapping data in-
cluded in GATExplorer. A type of files called ncRNA
Mapper was also obtained from GATExplorer, which
includes the probes that do not map to any coding re-
gion but that were mapped to a database for ncRNA of
human and mouse derived from RNAdb [27]. A cus-
tomized R script was used to perform a microarray ex-
pression calculation according to the re-mapping data
(file ncrnamapperhgu133plus2cdf_3.0) obtained from
public database NCBI.
The online software including ORF Finder (http://
www.ncbi.nlm.nih.gov/gorf/gorf.html), PhyloCSF (https://
github.com/mlin/PhyloCSF/wiki), and Coding Potential
Calculator (CPC; http://cpc.cbi.pku.edu.cn/) were used to
assessment of lncRNA protein-coding potential.
To gain further insight into the biologic pathways in-
volved in GC pathogenesis through LINC00261 pathway,
a Gene Set Enrichment Analysis (GSEA) was performed.
The gene sets showing FDR of 0.25, a well-established cut-
off for the identification of biologically relevant gene, were
considered enriched between classes under comparison.
5′ and 3′ rapid amplification of cDNA ends (RACE) analysis
We used the 5′ and 3′ RACE analyses to determine the
transcriptional initiation and termination site of GCASPC
using a SMARTer RACE cDNA Amplification kit (Clon-
tech, Palo Alto, CA, USA), according to the manufac-
turer’s instructions. PCR of the internal region was
performed when starting points of 5′ and 3′ RACE had
an unamplified gap. RACE PCR products were separated
on a 1.5 % agarose gel. Gel products were extracted with
the Gel and PCR Clean-Up System (Promega, A9282),
cloned into the pGEM-T Vector Systems I (Promega,
A3600) and sequenced bidirectionally using the M13
forward and reverse primers by Sanger sequencing at Invi-
trogen. At least five colonies were sequenced for every
RACE PCR product that was gel purified.
Cell lines
The human gastric adenocarcinoma cell lines MGC803,
BGC823, MKN28, MKN45, and SGC7901 and the nor-
mal gastric epithelial cell line (GES-1) were obtained
from the Chinese Academy of Sciences Committee on
Type Culture Collection cell bank (Shanghai, China).
MGC803, BGC823, and MKN28 cells were cultured in
Roswell Park Memorial Institute (RPMI) 1640 medium;
MKN45, GES-1, and SGC7901 cells were cultured in a
Dulbecco-modified Eagle medium (DMEM; GIBCO-
BRL) supplemented with 10 % fetal bovine serum (FBS),
100 U/ml penicillin, and 100 mg/ml streptomycin (Invi-
trogen, Carlsbad, CA, USA) at 37 °C in 5 % CO2.
Tissue samples and clinical data collection
In this study, we analyzed 138 patients who underwent
resection of primary GC at the 1st Affiliated Hospital of
Wenzhou Medical University, the affiliated People’s Hos-
pital of Jiangsu University, and the First People’s Hospital of
Yangzhou. All the patients were treated by 5-fluorouracil
(5-FU)-based chemotherapy after gastrectomy: oxaliplatin,
leucovorin, and 5-FU (modified FOLFOX) for 6 cycles. The
study was approved by the Ethics Committee on Human
Research of the 1st Affiliated Hospital of Wenzhou Medical
University, the affiliated People’s Hospital of Jiangsu Univer-
sity, and the First People’s Hospital of Yangzhou, and writ-
ten informed consent was obtained from all the patients.
The clinicopathological characteristics of the GC patients
are summarized in Table 1. All patients with GC have
been followed up at intervals of 1–2 months until April
2016, and the median follow-up period was 36 months
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(range, 20–48 months). Follow-up studies included
physical examination, laboratory analysis, and com-
puted tomography if necessary. DFS was defined as the
interval between the dates of surgery and recurrence; if
recurrence was not diagnosed, patients were censored
on the date of death or the last follow-up.
RNA preparation and quantitative real-time PCR
Total RNAs were extracted from tumorous and adjacent
normal tissues or cultured cells using Trizol reagent (Invi-
trogen) following the manufacturer’s protocol. RT and
qPCR kits (Takara, Dalian, China) were used to evaluate
the expression of LINC00261 in tissue samples and cul-
tured cells. The primers used in this study are shown in
Additional file 4: Table S1. Real-time PCR was performed
in triplicate, and the relative expression of LINC00261 was
calculated using the comparative cycle threshold (2−ΔΔCT)
method with glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) as the endogenous control to normalize the data.
Vector construction and transfection and siRNA
transfection
To overexpress LINC00261, the coding sequence of
LINC00261 was amplified and subcloned into the
pcDNA3.1 (+) vector (Invitrogen) according to the manufac-
turer’s instructions. BGC823 cells were then transfected with
a negative control vector or the LINC00261-expressing
plasmid using Lipofectamine 2000 (Invitrogen). To generate
LINC00261 knockdown MGC803 cells, the target sequence
for LINC00261 siRNA or scrambled siRNA that did not
correspond to any human sequence was synthesized
(Invitrogen). The siRNA sequences are shown in Additional
file 4: Table S1.
Cell proliferation assays
Cell viability was monitored using a Cell Proliferation Re-
agent Kit I (MTT; Roche Applied Science). MGC803 cells
transfected with si-LINC00261 (3000 cells/well) and
BGC823 cells transfected with Pcdna3.1-LINC00261 were
grown in 96-well plates. Cell viability was assessed every
24 h following the manufacturer’s protocol. All experi-
ments were performed in quadruplicate. For colony forma-
tion assays, Pcdna3.1-LINC00261-transfected BGC823
cells (n = 500) were placed in 6-well plates and maintained
in media containing 10 % FBS. The medium was replaced
every 4 days; after 14 days, the cells were fixed with metha-
nol and stained with 0.1 % crystal violet (Sigma-Aldrich).
Visible colonies were then counted. For each treatment
group, wells were assessed in triplicate, and experiments
were independently repeated three times.
Wound healing assay
For the wound healing assay, 3 × 105 cells were seeded
in 6-well plates, cultured overnight, and transfected with
pCDNA3.1-LINC00261, si-LINC00261, or a control.
Once cultures reached 85 % confluence, the cell layer
was scratched with a sterile plastic tip and washed with
culture medium. The cells were then cultured for 48 h with
medium containing 1 % FBS. At different time points, im-
ages of the plates were acquired using a microscope. The
distance between the two edges of the scratch was mea-
sured using the Digimizer software system. The assay was
independently repeated three times.
Cell migration and invasion assays
For the migration assays, at 48 h post-transfection, 5 ×
104 cells in serum-free media were placed into the upper
chamber of an insert (8-μm pore size; Millipore). For the
invasion assays, 1 × 105 cells in a serum-free medium
were placed into the upper chamber of an insert coated
with Matrigel (Sigma-Aldrich). The medium containing
10 % FBS was added to the lower chamber. After incuba-
tion for 24 h, the cells remaining on the upper membrane
were removed with cotton wool. Cells that had migrated
or invaded through the membrane were stained with
methanol and 0.1 % crystal violet, imaged, and counted
using an IX71 inverted microscope (Olympus, Tokyo,
Japan). Experiments were independently repeated three
times.
Western blot assay and antibodies
Cells were lysed using radioimmunoprecipitation assay
protein extraction reagent (Beyotime, Beijing, China)
supplemented with a protease inhibitor cocktail (Roche,
CA, USA) and phenylmethylsulfonyl fluoride (Roche).
The concentration of proteins was determined using a
Bio-Rad protein assay kit. Protein extracts (50 μg) were
separated by 10 % sodium dodecyl sulfate–polyacryl-
amide gel electrophoresis (SDS-PAGE), transferred to
nitrocellulose membranes (Sigma), and incubated with
specific antibodies. Electrochemiluminescent chromo-
genic substrate was used to visualize the bands, and the
intensity of the bands was quantified by densitometry
(Quantity One software; Bio-Rad), with GAPDH used
as a control. Antibodies (1:1000 dilutions) against E-
cadherin, N-cadherin, FN1, and Vimentin were pur-
chased from BD.
Metastasis assay in athymic mouse model
Male athymic mice (4 weeks old) were purchased from
the Animal Center of the Chinese Academy of Science
(Shanghai, China) and maintained in laminar flow cab-
inets under specific pathogen-free conditions. BGC823
cells transfected with pCDNA3.1-LINC00261 or the
empty vector were harvested from 6-well plates,
washed with phosphate-buffered saline (PBS), and re-
suspended at a density of 2 × 107 cells/ml. The cell
suspension (0.1 ml) was injected into the tail veins of
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10 mice, which were sacrificed 7 weeks after the injec-
tion. Metastasis focuses appeared mostly in the lung
upon tail vein injection of athymic mouse [10]. So the
lungs were removed and photographed, and visible
tumors on the lung surface were counted. This study
was carried out in strict accordance with the Guide for
the Care and Use of Laboratory Animals of the Na-
tional Institutes of Health. Our protocol was approved
by the Committee on the Ethics of Animal Experi-
ments of Wenzhou Medical University. All surgery
was performed under sodium pentobarbital anesthesia,
and all efforts were made to minimize suffering [28].
The metastasis assays in athymic mice were independ-
ently performed for two replicates.
Immunohistochemical analysis
The immunohistochemical analysis of E-cadherin, N-
cadherin, and Vimentin was performed according to a
previously described method [29]. Immunohistochemi-
cal score was semiquantitatively evaluated on the basis
of staining intensity and distribution using the immu-
noreactive score: intensity score× proportion score.
The staining intensity was scored as follows: 0, nega-
tive; 1, weak; 2, moderate; or 3, strong. The proportion
score was defined as follows: 0, negative; 1, 10 % or
less; 2, 11 to 50 %; 3, 51 to 80 %; or 4, 80 % or more
positive cells. The total score ranged from 0 to 12. The
immunoreactivity was divided into three levels on the
basis of the final score: negative expression was de-
fined as a total score of 0; low expression, as a total
score of 1 to 4; and high expression, as a total score
higher than 4. Immunoreactivity was assessed inde-
pendently by two investigators who were blinded to
the other immunohistochemical results.
Statistical analysis
All statistical analyses were performed using SPSS
20.0 software (IBM, SPSS, Chicago, IL, USA). The sig-
nificance of the differences between groups was esti-
mated by Student’s t test, χ2 test, or Wilcoxon test, as
appropriate. DFS rates were calculated by the Kaplan–
Meier method with the log-rank test applied for com-
parison. Survival data were evaluated using univariate
and multivariate Cox proportional hazards models.
Variables with a value of P < 0.05 in univariate analysis
were used in subsequent multivariate analysis on the
basis of Cox regression analyses. Pearson correlation
analyses were performed to investigate the correlation
among LINC00261 with E-cadherin, N-cadherin, and
FN1 expressions. Two-sided P values were calculated,
and a probability level of 0.05 was chosen for statis-
tical significance.
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